The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...
During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III ...
The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback